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Abstract
Background—Multiple clinical trials have shown that neoadjuvant systemic therapy has a 
benefit in women who are borderline lumpectomy candidates and in those with locally-advanced 
breast cancers by reducing the mastectomy rate and making inoperable tumors operable. The study 
aim was to examine the patterns of neoadjuvant chemotherapy and endocrine therapy use among 
younger women in the US treated at different types of cancer centers.
Study Design—Data from the National Cancer Data Base for 118,086 women younger than 65 
with clinical stage IIA (T2N0 only) to IIIC breast cancer. Following the National Comprehensive 
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Cancer Network guideline categorization, patients were grouped into those who were borderline 
lumpectomy candidates (clinical stage IIA [T2N0 only], IIB, or IIIA [T3N1 only]) or those with 
locally-advanced disease (clinical stage IIIA [T0-3N2 only], IIIB, or IIIC). The main outcome was 
the proportion of women who received neoadjuvant systemic therapy.
Results—Use of neoadjuvant chemotherapy ranged from 17% (stage IIA) to 79% (stage IIIB). 
Across almost all stage and receptor subtypes, the use was lower in community vs. academic 
centers. On multivariable analysis, use of neoadjuvant chemotherapy was decreased in community 
vs. academic centers (borderline lumpectomy candidates, aRR 0.73, 95% CI 0.69–0.77; locally-
advanced disease, aRR 0.78, 95% CI 0.74–0.83).
Conclusions—Use of guideline-concordant neoadjuvant chemotherapy is significantly higher 
among women treated at academic vs. community centers in young and healthy women who do 
not commonly have contraindications to this treatment. Our study identified a potential disparity in 
cancer care by type of center where patients receive treatment.
INTRODUCTION
Neoadjuvant chemotherapy benefits two specific groups of breast cancer patients. The first 
group includes patients with inoperable locally-advanced disease, as neoadjuvant 
chemotherapy can reduce the tumor burden and therefore make the tumor resectable with 
either a mastectomy or lumpectomy.1,2 C7784, a phase 3 study from the Cancer and 
Leukemia Group B (now the Alliance for Clinical Trials in Oncology), found that of 113 
stage III inoperable breast cancer patients, 81% were deemed operable after neoadjuvant 
chemotherapy.2 The second group includes patients who desire breast conservation but have 
tumors too large for lumpectomy; for these patients, neoadjuvant chemotherapy may shrink 
the tumor enough to allow breast conservation. Long-term follow-up of the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 and the European Organization 
for the Research and Treatment of Cancer (EORTC) 10902 trials showed that neoadjuvant 
vs. adjuvant chemotherapy was associated with an absolute risk reduction for mastectomy of 
7% and 13%, respectively.3,4
Endocrine therapy can also be used neoadjuvantly to reduce tumor burden. Multiple clinical 
trials have shown that neoadjuvant endocrine therapy alone produces objective responses in 
up to 70% of women, and can also reduce the mastectomy rate and improve operability in 
these patients.5–7
Based on these data, published guidelines recommend neoadjuvant systemic therapy for 
patients with locally-advanced breast cancers, as well as patients who are borderline 
lumpectomy candidates and desire breast conservation.8 However, the patterns of utilization 
of neoadjuvant chemotherapy and endocrine therapy in younger women with breast cancer 
are unknown – and this was the main objective of this study. The primary focus of the study 
was to examine patterns of use of neoadjuvant systemic therapy across the US for women 
with locally-advanced (including inflammatory) breast cancers. Further, we were interested 
in examining whether use of neoadjuvant systemic therapy differed by the type of cancer 
center where patients received care – academic vs. comprehensive community (treating >500 
patients per year) vs. smaller community centers. A secondary focus of the study was to 
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examine patterns of neoadjuvant systemic therapy use in women with potentially borderline 
lumpectomy-eligible cancers. We focused on younger women because neoadjuvant therapy 
may be especially appropriate for this group, who may value breast preservation and are also 
less likely to have contraindications (such as comorbidities) to receiving neoadjuvant 
therapy. We examined data from the National Cancer Data Base (NCDB), a national cancer 




The NCDB is jointly maintained by the American College of Surgeons’ Commission on 
Cancer (CoC) and the American Cancer Society.9 All institutions accredited by the CoC 
report data using standardized coding definitions as specified by the CoC’s Facility 
Oncology Registry Data Standards. The NCDB contains information on patient 
demographics, comorbidity score (Charlson-Deyo), county-level socioeconomic attributes, 
facility characteristics, cancer diagnosis and tumor characteristics, and first course of 
treatment. Facilities are classified as “academic/research,” “comprehensive community 
cancer program” (defined as treating >500 new patients per year), or “community cancer 
program” (treating 100–500 patients per year).
Patient Cohort
In this study, we searched the NCDB for women younger than 65 with incident breast 
cancers diagnosed from 2006–2012 (eFigure 1). Patients with prior cancer diagnoses were 
excluded. This study focused on patients with clinical stage IIA (T2N0 only), IIB, IIIA, IIIB, 
and IIIC disease because these are the stages that the National Comprehensive Cancer 
Network (NCCN) guidelines consider eligible for neoadjuvant systemic therapy.8 Patients 
with incomplete data on stage, receipt of systemic therapy, or primary surgery were 
excluded. Among patients who were excluded because they did not undergo surgery, 76% 
received chemotherapy, though it is not possible to know whether the intention was 
neoadjuvant. The study sample was limited to patients with ductal, lobular, mixed ductal and 
lobular, or inflammatory histologies (International Classification of Diseases for Oncology 
[3rd edition] histology codes 8500–8508, 8520–8524, and 8530). This resulted in an analytic 
sample of 118,086 patients.
Outcome Definition and Statistical Analysis
Patients were stratified into two groups based on NCCN guideline categorization: locally-
advanced disease (stage IIIA [T0-3N2 only], IIIB, and IIIC) and stages that are borderline 
eligible for lumpectomy (IIA [T2N0 only], IIB, and IIIA [T3N1 only]). We used number of 
days from diagnosis to each modality of treatment to identify patients who received systemic 
therapy before surgery. Descriptive statistics summarized the proportion of patients who 
received no neoadjuvant therapy, neoadjuvant endocrine therapy alone, or neoadjuvant 
chemotherapy (with/without endocrine therapy), stratified by type of center (academic, 
comprehensive community, or community). Because NCDB did not systematically collect 
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HER2 status until 2010, analysis of neoadjuvant therapy use based on HER2 status was 
limited to patients from 2010–2012.
Multivariable Poisson regression with a robust variance assessed the association between 
treatment facility type and receipt of neoadjuvant chemotherapy, while controlling for 
patient sociodemographic and diagnostic covariates. Separate models were constructed for 
patients with locally-advanced or borderline lumpectomy-eligible disease.10 Four versions of 
the model were run: two included patients from each group diagnosed 2006–2012 and did 
not include HER2 status as a covariate, while the other two models included only patients 
diagnosed 2010–2012 and did include HER2 as a covariate. We further assessed the 
discriminatory ability of a variety of logistic regression models to determine neoadjuvant 
chemotherapy receipt by comparing the area under the receiver operating curve. Models 
included combinations of calendar year and patient, tumor, hospital and geographic 
characteristics.
All statistical analyses were performed with SAS software version 9.4 (SAS Institute Inc., 
Cary, NC, USA), and two-sided p<.05 was considered statistically significant.
RESULTS
Table 1 describes the characteristics of the 118,086 patients included in this study, including 
20,720 with locally-advanced cancers (stages IIIA [T0-3N2 only], IIIB, IIIC), and 97,366 
borderline lumpectomy-eligible (stages IIA [T2N0 only], IIB, IIIA [T3N1 only]); these 
groupings were made based on NCCN guidelines.8 Overall, 72% were White, 79% had 
private insurance, and 66% were treated in comprehensive community or community 
centers. By design, analyzed patients were women younger than 65; 99% had no or little 
comorbidity.
Overall, use of neoadjuvant endocrine therapy alone was rare (2% or less) for all stages 
(Table 2). For patients with locally-advanced cancers, use of neoadjuvant chemotherapy 
(with or without neoadjuvant endocrine therapy) was especially high in those with T4 
disease (79% for stage IIIB [non-inflammatory], and 93% for inflammatory breast cancer). 
For patients in the borderline lumpectomy group, use of neoadjuvant chemotherapy 
increased with stage (from 17% for IIA to 74% for IIIA). Within each treatment type (no 
chemotherapy vs. neoadjuvant chemotherapy vs. adjuvant chemotherapy) the absolute 
difference in mastectomy rate between academic, community, and comprehensive 
community centers was relatively small (Table 3).
eFigure 2 shows use of neoadjuvant chemotherapy over time in patients treated at different 
types of centers. Consistently across the years studied (2006–2012), utilization of 
neoadjuvant chemotherapy was higher in academic centers vs. community centers. Table 4 
provides more detailed data on the proportion of patients who received neoadjuvant 
chemotherapy stratified by type of treatment facility, clinical stage, and tumor receptor 
subtype. In almost all patient groups by stage and receptor subtype, neoadjuvant 
chemotherapy use was lowest in community centers and highest in academic centers. For 
example, for women with inflammatory breast cancers, receipt of neoadjuvant chemotherapy 
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was 95% (academic) vs. 85% (community) in HR−/HER2+ disease, and 95% (academic) vs. 
88% (community) in HR+/HER2− disease.
Table 5 and eTable 1 summarize the multivariable models examining factors associated with 
neoadjuvant chemotherapy use. Table 5 included only patients from 2010–2012, for whom 
HER2 information is available; eTable 1 included patients from 2006–2012 and that model 
did not include HER2 status as a covariate. The multivariable models consistently 
demonstrated a lower use of neoadjuvant chemotherapy in community centers compared to 
academic centers (for community cancer program, aRR 0.73, 95% CI 0.69–0.77 for 
borderline lumpectomy-eligible patients; aRR 0.78, 95% CI 0.74–0.83 for locally-advanced 
patients). Other significant covariates included older age and higher comorbidity score 
which were associated with lower odds of receiving neoadjuvant chemotherapy; and high-
grade tumors and certain receptor subtypes (including HER2+ and HR−) were associated 
with higher odds of receiving neoadjuvant chemotherapy. Use of neoadjuvant chemotherapy 
was modestly higher in 2012 compared to 2006 (OR 1.08, 95% CI 1.03–1.12 for borderline 
lumpectomy-eligible cancers; aRR 1.20, 95% CI 1.15–1.25 for locally-advanced).
Forest plots (Figure 1) illustrate adjusted risk ratios (aRR) of neoadjuvant chemotherapy use 
in different patient subgroups, with an aRR less than 1 indicating less use compared to the 
reference group. When adding groups of covariates sequentially (year of diagnosis, then the 
group of patient characteristics, then tumor characteristics, then hospital characteristics), the 
AUC of the multivariable model increased most dramatically when tumor characteristics 
were added (AUC increase from 59.7 to 77.5% in borderline lumpectomy-candidate 
patients; AUC from 56.8 to 75.9% for locally-advanced patients) – suggesting that this 
group of covariates may represent the strongest determinants of whether patients received 
neoadjuvant chemotherapy.
DISCUSSION
In this study using data from the National Cancer Data Base, which includes ~70% of cancer 
patients across the US, use of neoadjuvant chemotherapy for younger and generally healthy 
women was highest at academic centers and lowest at community centers, even after 
controlling for clinical and sociodemographic variables; this finding was seen in women 
with locally-advanced breast cancers as well as those with potentially borderline 
lumpectomy-eligible cancers. The use of neoadjuvant chemotherapy generally increased 
with stage, while use of neoadjuvant endocrine therapy alone was rare. Hormone receptor-
negative and HER2-positive subtypes were associated with greater use of neoadjuvant 
chemotherapy.
While disparities in oncologic treatments and outcomes by patient race and insurance status 
have been consistently demonstrated in the published literature,11–14 whether rates of 
guideline-concordant care differ by where breast cancer patients receive treatment have not 
been fully described. A study by Cliby et al. used NCDB data to show that treatment at an 
academic center was independently associated with a higher rate of guideline-concordant 
care for ovarian cancer.15 The authors conclude that “targeting where patients receive care 
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and ensuring delivery of guideline care should be a high priority given their associations 
with outcomes.”15
The primary focus of this study was on the use of neoadjuvant systemic therapy for women 
with locally-advanced breast cancers. For this group of patients, the NCCN guidelines 
recommend neoadjuvant chemotherapy before surgery.8 A novel finding of this study is that 
the use of neoadjuvant chemotherapy differed by type of cancer center: in almost all 
subgroups by stage and histologic subtype, patient receipt of neoadjuvant chemotherapy was 
higher in academic centers compared to community centers. In women with locally-
advanced cancers, the difference between academic and community centers was large for 
several subgroups. For example, in patients with stage IIIC non-inflammatory breast 
cancers, the proportion of patients who received neoadjuvant chemotherapy differed between 
academic and community centers by as much as 27%. In patients with inflammatory breast 
cancers, difference between academic and community centers was as high as 10% (in HR−/
HER2+ subtype). The reason behind this observed underuse of chemotherapy for some 
women with locally-advanced breast cancers is unknown, especially because in this study 
we specifically examined a younger group of patients. It is possible that physicians at 
smaller community centers are less likely to offer neoadjuvant chemotherapy, and/or patients 
in these centers are more likely to refuse this treatment. It is also possible that differential 
access to oncologic care across different centers may contribute to this observed disparity, 
but more research is needed.
A similar finding of differential use of neoadjuvant chemotherapy across types of centers 
was also seen in women with potentially borderline lumpectomy-eligible tumors. In breast 
cancer, multiple publications have documented a concerning trend of increased mastectomy 
rates in recent years.16–18 Neoadjuvant systemic therapy can benefit patients by reducing the 
need for mastectomy. The NSABP B-18, EORTC 10902, and Alliance 40603 trials 
demonstrated that neoadjuvant chemotherapy is effective in making large, operable tumors 
eligible for lumpectomy.3,4,19 Thus, for women with select clinical stage IIA [T2N0 only] to 
IIIA [T3N1 only] cancers, the NCCN guidelines recommend consideration of neoadjuvant 
systemic therapy in patients who desire breast conservation. This study found, for example, 
in clinical stage IIIA [T3N1 only] patients across receptor subtypes, receipt of neoadjuvant 
chemotherapy was lower in community centers vs. academic centers by an absolute 
difference of 6 to 18%. Thus, patients who are borderline lumpectomy candidates treated at 
community centers may be less frequently offered the opportunity to use neoadjuvant 
treatment to achieve breast conservation; alternatively, patients at these centers may be less 
willing to accept upfront chemotherapy.
An additional novel finding of this study was that neoadjuvant chemotherapy use differed by 
receptor subtype. Data from prior clinical trials Alliance 40603, NeoSphere, and American 
College of Surgeons Oncology Group (ACOSOG) Z1031 suggested that the pathologic 
complete response (pCR) rate from neoadjuvant systemic therapy may be higher for patients 
with triple-negative or HER2-positive breast cancers compared to hormone receptor-positive 
disease.19–21 In the Alliance 40603 trial, the pCR rate for patients with triple negative breast 
cancers was 54%.19 The NeoSphere trial which included HER2-positive breast cancer 
patients reported a 46% pCR rate after neoadjuvant trastuzumab, pertuzumab and docetaxel.
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20 In contrast, the ACOSOG Z1031 trial which included ER-positive breast cancer patients 
demonstrated a 2% pCR rate after neoadjuvant exemestane.21 While NCCN guidelines do 
not distinguish between the receptor subtypes when recommending neoadjuvant systemic 
therapy, our findings suggest that physicians do take this into account.
Another novel finding of this study is the very low rate of neoadjuvant endocrine therapy use 
across the United States. To our knowledge this is the first study to report the patterns of use 
of neoadjuvant endocrine therapy. The Immediate Preoperative Anastrazole, Tamoxifen, or 
Combined with Tamoxifen (IMPACT) and Preoperative ‘Arimidex’ Compared to Tamoxifen 
(PROACT) trials, published in 2005 and 2006 respectively, showed that neoadjuvant 
endocrine therapy alone reduces mastectomy rates.5,6 The influence of these European 
studies on patterns of use in the United States appears to be small, as <2% of patients receive 
this treatment across all patient subgroups examined.
There are several potential limitations of this study. For example, we examined a group of 
patients whom by stage are classified as “borderline lumpectomy candidates” in NCCN 
guidelines. However, whether each individual can pursue breast conservation can only be 
determined clinically. It is possible that our finding of a lower use of neoadjuvant 
chemotherapy in community centers for this group of borderline lumpectomy patients can be 
explained by a difference in patient population; that is, within the same clinical stage, 
community cancer center patients could have smaller tumors and larger breasts than patients 
at academic centers. Missing data on use of neoadjuvant systemic therapy was another 
limitation – we found the rate of missingness was low and similar across facility types (5.0% 
for community centers, 4.7% comprehensive community centers, and 5.3% academic 
centers). However, we do not know if there was misclassification in the data – i.e. if some 
patients with missing chemotherapy data were erroneously coded as not receiving treatment. 
Additionally, the NCDB cannot take into account patient preference for type of surgery and 
therefore whether to pursue neoadjuvant vs. adjuvant chemotherapy. However, it is unlikely 
that these patient differences fully explain our consistent findings of a lower use of 
neoadjuvant chemotherapy in community centers across almost all stage and receptor 
subtype patient subgroups.
In summary, the use of guideline-concordant neoadjuvant chemotherapy for younger women 
with locally-advanced or borderline lumpectomy-eligible breast cancers was higher in 
academic centers compared to community centers. This study specifically focused on 
younger women who were unlikely to have contraindications to systemic therapy, and we 
found a difference in the use of neoadjuvant treatment consistently across stage and receptor 
subtypes. Our study has identified an additional potential disparity in cancer care by type of 
center where patients receive treatment. Further research is needed to explore ways to ensure 
that patients treated across academic and community cancer centers receive similar quality 
of care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Forest plot of adjusted risk ratios and areas under the receiver operating curve among (A) 
AJCC clinical stage IIA (T2N0), IIB, or IIIA (T3N1), or (B) stage IIIA (T0-3N2), IIIB, or 
IIIC breast cancer*
Abbreviations: aRR, adjusted risk ratio. AUC, area under the receiver operating curve. NH, 
non-Hispanic. Unk, unknown. Govt, government. HR, hormone receptor. HER2, human 
epidermal growth factor receptor-2. Non, non-inflammatory.
*Risk ratios greater than 1 indicate higher likelihood of receiving neoadjuvant chemotherapy 
compared to the reference group. Risk ratios less than 1 indicate a lower likelihood of 
receiving neoadjuvant chemotherapy compared to the reference group.
Sample size included for the models were: A (N=43,396), B (N=7,705).
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  <50 44,824 (46) 9,289 (45) 54,113 (46)
  50–54 19,150 (20) 4,078 (20) 23,228 (20)
  55–59 17,676 (18) 4,009 (19) 21,685 (18)
  60–64 15,716 (16) 3,344 (16) 19,060 (16)
Race** <.0001
  White non-Hispanic 66,293 (73) 13,135 (68) 79,428 (72)
  Black non-Hispanic 13,681 (15) 3,726 (19) 17,407 (16)
  Hispanic 6,884 (8) 1,721 (9) 8,605 (8)
  Other 4,570 (5) 795 (4) 5,365 (5)
Insurance status <.0001
  Private 78,113 (80) 14,914 (72) 93,027 (79)
  Medicaid 12,205 (13) 3,828 (19) 16,033 (14)
  Other government 1,361 (1) 284 (1) 1,645 (1)
  None or unknown 5,687 (6) 1,694 (8) 7,381 (6)
Year of Diagnosis <.0001
  2006 7,359 (8) 2,185 (11) 9,544 (8)
  2007 8,968 (9) 2,516 (12) 11,484 (10)
  2008 13,345 (14) 3,198 (15) 16,543 (14)
  2009 15,222 (16) 3,178 (15) 18,400 (16)
  2010 17,188 (18) 3,420 (17) 20,608 (18)
  2011 17,769 (18) 3,232 (16) 21,001 (18)
  2012 17,515 (18) 2,991 (14) 20,506 (17)
Charlson/Deyo Comorbidity Score .09
  0 86,755 (89) 18,369 (89) 105,124 (89)
  1 9,260 (10) 2,031 (10) 11,291 (10)
  2+ 1,351 (1) 320 (2) 1,671 (1)
Facility location* <.0001
  South 37,203 (38) 8,416 (41) 45,619 (39)
  Midwest 26,188 (27) 5,313 (26) 31,501 (27)
  Northeast 17,048 (18) 3,634 (18) 20,682 (18)
  West 16,927 (17) 3,357 (16) 20,284 (17)
































  Academic/research 32,501 (33) 6,867 (33) 39,368 (33)
  Comprehensive community cancer program 55,206 (57) 11,448 (55) 66,654 (56)
  Community cancer program 9,659 (10) 2,405 (12) 12,064 (10)
Population density .04
  Non-rural 92,698 (98) 19,646 (98) 112,344 (98)
  Rural 1,517 (2) 362 (2) 1,879 (2)
Tumor grade <.0001
  1 8,457 (9) 952 (5) 9,409 (8)
  2 34,790 (38) 6,303 (33) 41,093 (37)
  3+ 49,316 (53) 11,808 (62) 61,124 (55)
HR Summary (Years 2006–2009) <.0001
  ER+ or PR+ 13,859 (32) 4,076 (38) 36,858 (67)
  ER and PR− or borderline 30,134 (69) 6,724 (62) 17,935 (33)
HR/HER2 summary (Years 2010–2012) <.0001
  HR+/HER2− 29,420 (60) 4,473 (49) 33,893 (58)
  HR+/HER2+ 6,618 (13) 1,464 (16) 8,082 (14)
  HR−/HER2+ 3,281 (7) 1,081 (12) 4,362 (8)
  HR−/HER2− 10,045 (20) 2,061 (23) 12,106 (21)
AJCC Clinical Stage ---
  IIA (T2N0 only) 58,781 (60) - 58,781 (50)
  IIB 30,636 (32) - 30,636 (26)
  IIIA (T3N1 only) 7,949 (8) - 7,949 (7)
  IIIA (T0-3N2 only) - 8,024 (39) 8,024 (7)
  IIIB non-inflammatory - 4,884 (24) 4,884 (4)
  IIIC non-inflammatory - 4,221 (20) 4,221 (4)
  Inflammatory (T4d) - 3,591 (17) 3,591 (3)
Histology
  Invasive ductal carcinoma 82,992 (85) 17,030 (82) <.0001 100,022 (85)
  Invasive lobular carcinoma 9,101 (9) 1,457 (7) 10,558 (9)
  Mixed ductal and lobular 5,229 (5) 944 (5) 6,173 (5)
  Inflammatory 44 (<1) 1,289 (6) 1,333 (1)
Laterality <.0001
  Unilateral 97,331 (>99) 20,697 (>99) 118,028 (>99)
  Bilateral 35 (<1) 23 (<1) 58 (<1)
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Abbreviations: AJCC, American Joint Committee on Cancer. HR, Hormone Receptor. HER2, Human Epidermal Growth Factor Receptor 2.
**
Approximately 6% of patients had missing information on race.
*
South includes Washington DC, Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, 
Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas; Midwest includes Illinois, Indiana, Michigan, Ohio, Wisconsin, 
Iowa, Kansas, Minnesota, Missouri, North Dakota, Nebraska, South Dakota; Northeast includes Connecticut, Massachusetts, Maine, New 
Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania; West includes Arizona, Colorado, Idaho, Montana, New Mexico, 
Nevada, Utah, Wyoming, Alaska, California, Hawaii, Oregon, and Washington.
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Table 2












IIA (T2N0 only) 594 (1) 10,126 (17) 48,061 (82)
<.0001IIB (T2N1, T3N0) 299 (1) 13,656 (45) 16,681 (54)
IIIA (T3N1 only) 75 (1) 5,865 (74) 2,009 (25)
IIIA (T0-3N2 only) 50 (1) 3,546 (44) 4,428 (55)
<.0001
IIIB non-inflammatory (T4N0-2) 81 (2) 3,871 (79) 932 (19)
IIIC non-inflammatory (N3) 27 (1) 2,231 (53) 1,963 (47)
Inflammatory (T4d) 5 (<1) 3,353 (93) 233 (7)
*
With or without neoadjuvant endocrine therapy
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Table 3









No chemotherapy 2,892 (52) 5,094 (51) 814 (45) <.0001
Neoadjuvant chemotherapy +/− adjuvant chemotherapy 10,769 (68) 16,257 (70) 2,502 (70) .002
Adjuvant chemotherapy only 11,168 (62) 20,084 (60) 3,757 (56) <.0001
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Table 5














  <50 1 1
  50–54 0.87 (0.84, 0.90) <.001 0.96 (0.92, 0.99) .02
  55–59 0.83 (0.80, 0.86) <.001 0.93 (0.89, 0.97) <.001
  60–64 0.69 (0.66, 0.72) <.001 0.86 (0.82, 0.90) <.001
Race
  White non-Hispanic 1 1
  Black non-Hispanic 1.02 (0.98, 1.05) .41 1.06 (1.02, 1.10) .002
  Hispanic 1.01 (0.96, 1.06) .83 1.01 (0.96, 1.07) .63
  Other 0.98 (0.92, 1.04) .45 1.05 (0.98, 1.13) .18
Insurance status
  Private 1 1
  Medicaid 1.01 (0.97, 1.05) .64 0.97 (0.94, 1.01) .13
  Other government 0.96 (0.86, 1.07) .43 0.94 (0.82, 1.08) .35
  None or unknown 1.05 (1.00, 1.11) .06 0.99 (0.94, 1.04) .64
Year of Diagnosis
  2010 1 1
  2011 1.09 (1.05, 1.12) <.001 1.05 (1.01, 1.09) .009
  2012 1.12 (1.09, 1.16) <.001 1.09 (1.05, 1.13) <.001
Charlson/Deyo Comorbidity Score
  0 1 1
  1 0.86 (0.82, 0.91) <.001 0.93 (0.89, 0.98) .006
  2+ 0.72 (0.62, 0.83) <.001 0.85 (0.73, 0.98) .02
Facility region
  South 1 1
  Midwest 0.96 (0.92, 0.99) .005 1.02 (0.99, 1.06) .24
  Northeast 0.88 (0.85, 0.91) <.001 0.90 (0.86, 0.94) <.001
  West 0.91 (0.88, 0.95) <.001 0.98 (0.93, 1.02) .33
Facility type
  Academic/research 1 1
  Comprehensive community cancer program 0.90 (0.88, 0.93) <.001 0.92 (0.90, 0.95) <.001
  Community cancer program 0.73 (0.69, 0.77) <.001 0.78 (0.74, 0.83) <.001
Population density


























  Rural 1 1
  Non-rural 1.13 (1.01, 1.28) .04 1.01 (0.89, 1.13) .93
Tumor grade
  1 1 1
  2 1.24 (1.16, 1.33) <.001 1.17 (1.05, 1.29) .003
  3+ 1.21 (1.13, 1.30) <.001 1.17 (1.06, 1.29) .003
HR/HER2 summary
  HR+/HER2− 1 1
  HR+/HER2+ 1.50 (1.44, 1.55) <.001 1.06 (1.01, 1.10) .02
  HR−/HER2+ 1.69 (1.62, 1.77) <.001 1.17 (1.12, 1.22) <.001
  HR−/HER2− 1.70 (1.65, 1.77) <.001 1.22 (1.17, 1.27) <.001
AJCC Clinical Stage
  IIA (T2N0 only) 1 -
  IIB 2.49 (2.41, 2.57) <.001 -
  IIIA (T3N1 only) 3.91 (3.78, 4.04) <.001 -
  IIIA (T0-3N2 only) - 1
  IIIB non-inflammatory - 1.62 (1.55, 1.69) <.001
  IIIC non-inflammatory - 1.20 (1.14, 1.26) <.001
  Inflammatory (T4d) - 1.86 (1.79, 1.94) <.001
Histology
  Invasive ductal carcinoma 1 1
  Invasive lobular carcinoma 0.76 (0.72, 0.81) <.001 0.84 (0.77, 0.92) <.001
  Mixed ductal and lobular 0.81 (0.75, 0.87) <.001 0.84 (0.77, 0.93) <.001
  Inflammatory 2.00 (1.53, 2.62) <.001 1.06 (1.03, 1.10) .0003
Laterality
  Unilateral 1 1
  Bilateral 0.48 (0.06, 3.63) .48 0.81 (0.49, 1.34) .41
Abbreviations: aRR, adjusted risk ratio. AJCC, American Joint Committee on Cancer. HR, Hormone Receptor. HER2, Human Epidermal Growth 
Factor Receptor 2.
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